BioCentury
ARTICLE | Clinical News

ND0612L: Phase II data

November 10, 2014 8:00 AM UTC

Top-line data from 30 patients with moderate to severe PD in the first part of a 2-part, double-blind Phase II trial showed that subcutaneous ND0612L as an adjunct to patients' oral medications met th...